Annexin V is a protein your body naturally produces that binds to dying cells and acts as a built-in anticoagulant on blood vessel surfaces. It has become one of the most widely used tools in biomedical research for detecting cell death, but it also plays important roles inside the body, from preventing unwanted blood clots to regulating how damaged cells are cleared away.
How Annexin V Works at the Molecular Level
Annexin V is a relatively small protein, roughly 64 by 40 by 30 angstroms in size, folded into four structural domains that each form a compact bundle of helices. What makes it biologically interesting is its strong attraction to a specific fat molecule called phosphatidylserine, or PS. This binding only happens when calcium is present, which is why Annexin V is described as a “calcium-dependent phospholipid-binding protein.”
In healthy cells, phosphatidylserine stays tucked on the inner side of the cell membrane, hidden from the outside world. When a cell begins to die through a controlled process called apoptosis, phosphatidylserine flips to the outer surface. Annexin V locks onto that exposed phosphatidylserine with extremely high affinity. This flip-and-bind mechanism is the foundation of nearly everything Annexin V is used for in medicine and research.
Its Natural Role as an Anticoagulant
Before Annexin V became a lab tool, it was first identified in 1985 as a “vascular anticoagulant protein” found on blood vessel walls. On cell surfaces where phosphatidylserine is exposed (such as injured or activated cells), Annexin V forms a rigid, crystal-like shield over those exposed fat molecules. This shield physically blocks clotting factors from assembling on the membrane, which prevents blood clots from forming at that site. The inhibition is remarkably efficient: Annexin V can suppress more than 99% of the enzyme activity that drives clot formation, not by removing clotting factors entirely but by restricting their ability to move and interact on the membrane surface.
This anticoagulant shield has real clinical significance. In antiphospholipid syndrome, a condition that causes abnormal blood clotting and pregnancy complications, antibodies disrupt the Annexin V shield on cell membranes. Once the shield is broken, clotting factors gain access to the exposed phospholipids and can trigger dangerous clots. In pregnant women with this condition, loss of the Annexin V shield on placental cells can initiate clot formation that interferes with fetal nutrition and contributes to pregnancy loss.
Detecting Cell Death in the Lab
The most common use of Annexin V today is as a laboratory marker for apoptosis. Researchers attach a fluorescent tag to the protein, then expose cells to it. Because Annexin V binds specifically to phosphatidylserine on the outer membrane, cells that are undergoing apoptosis light up under detection instruments while healthy cells stay dark. Studies in Burkitt lymphoma cell lines and other cell types have confirmed that this staining reliably corresponds to the physical signs of apoptosis, such as the condensation and fragmentation of DNA inside the cell’s nucleus.
To get a fuller picture, researchers typically pair Annexin V with a second dye called propidium iodide, which can only enter cells whose membranes have completely broken down. This combination sorts cells into distinct categories. Cells that stain positive for Annexin V alone are in early apoptosis: their membranes are still intact, but phosphatidylserine has flipped to the outside. Cells positive for both Annexin V and propidium iodide are in late apoptosis or have died through necrosis, meaning their membranes are compromised. And cells negative for both markers are alive and healthy. This two-marker system, run through a technique called flow cytometry, has become a standard assay in cell biology, immunology, and drug development.
Applications in Cancer Imaging
Because Annexin V reliably finds dying cells, researchers have explored using it as an imaging agent to see whether cancer treatments are working inside the body. In a Phase I clinical study, 15 patients with lung cancer, lymphoma, or breast cancer received a radioactively labeled form of Annexin V before and shortly after their first round of chemotherapy. Before treatment, no uptake of the tracer appeared at tumor sites. Within 24 to 48 hours after chemotherapy, however, seven patients showed clear tracer uptake in their tumors, indicating that cancer cells were dying.
The results were striking: all seven patients with early tracer uptake went on to have either a complete or partial response to treatment over the following months. Of the eight patients who showed no uptake, six had progressive disease. Overall survival and progression-free survival were both significantly linked to whether the tracer appeared after the first treatment cycle. The concept is powerful because it could allow oncologists to see within a day or two whether a given chemotherapy regimen is actually killing tumor cells, rather than waiting months for imaging scans to show whether the tumor has shrunk.
Beyond Apoptosis Detection
While its role in detecting cell death gets the most attention, Annexin V participates in a surprisingly wide range of biological processes. It helps transport small membrane-bound packages called vesicles within cells. It plays a part in the mineralization process that builds bone and other hard tissues in the body. Research has also linked it to mechanisms involved in Alzheimer’s disease, where it may contribute to the neurotoxic effects seen in affected brain tissue. And in cancer biology beyond imaging, Annexin V appears to have direct inhibitory effects on tumor cell growth, though the precise pathways are still being mapped out.
The exposure of phosphatidylserine on dying cells also serves as an “eat me” signal for immune cells called macrophages, which are responsible for cleaning up dead and damaged cells. Annexin V’s binding to these same phosphatidylserine molecules places it at the intersection of cell death and immune clearance, two processes that are central to everything from wound healing to autoimmune disease.